Eltrombopag safety and efficacy for primary chronic XXXX in clinical practice.

@entity1 @entity3039 @entity548
BACKGROUND: Eltrombopag is effective and safe in chronic @entity3039 ( @entity3039 ). However, clinical trials may not accurately reflect what happens in clinical practice. We evaluated the efficacy and safety of eltrombopag in primary chronic @entity3039 in a real-world setting. METHODS: 164 primary chronic @entity3039 @entity1 from 40 Spanish centers, who had been treated with eltrombopag, were retrospectively evaluated. RESULTS: The median age of our cohort (72% @entity1 ) was 63 years (interquartile range, IQR, 45-75 years). The median time with @entity3039 diagnosis was 81 months (IQR, 30-192 months). The median number of therapies prior to eltrombopag was 3 (IQR, 2-4). At the time of eltrombopag start, 45 @entity1 (30%) were receiving concomitant treatment for @entity3039 . Forty-six @entity1 (30%) had @entity548 signs/symptoms the month before treatment start. The median platelet count at eltrombopag initiation was 22 x 10(9) /L (IQR, 8-39 x 10(9) /L). 135 @entity1 (88.8%) achieved a platelet response. The median time to platelet response was 12 days (95% CI, 9-13 days). Maintained platelet response rate during the 15-month period under examination was 75.2%. 28 @entity1 (18.4%) experienced adverse events, mainly grades 1-2. CONCLUSION: Eltrombopag is highly effective and well tolerated in unselected @entity1 with primary chronic @entity3039 . This article is protected by copyright. All rights reserved.
